StockNews.AI
DTIL
StockNews.AI
27 days

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

1. FDA granted Orphan Drug Designation for DTIL's PBGENE-DMD. 2. This designation supports DTIL's growth potential in gene therapies.

2m saved
Insight
Article

FAQ

Why Bullish?

Orphan Drug Designation typically boosts stock prices in biotech firms. Historical example includes CRSP, which surged post designation.

How important is it?

The designation is likely to attract investor interest, highlighting DTIL's innovation in gene editing.

Why Long Term?

Orphan Drug Designation may lead to expedited development and market exclusivity, enhancing long-term revenue prospects.

Related Companies

CRSPEDITNTLA
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). “Receipt of Orphan Drug Designation from the FDA for PBGENE-DMD underscores the tremendou.

Related News